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At present, no research criteria exist for the diagnosis of prodromal behavioural variant frontotemporal dementia
(bvFTD), though early detection is of high research importance. Thus, we sought to develop and validate a proposed set of research criteria for prodromal bvFTD, termed ‘mild behavioural and/or cognitive impairment in
bvFTD’ (MBCI-FTD).
Participants included 72 participants deemed to have prodromal bvFTD; this comprised 55 carriers of a pathogenic
mutation known to cause frontotemporal lobar degeneration, and 17 individuals with autopsy-confirmed frontotemporal lobar degeneration. All had mild behavioural and/or cognitive changes, as judged by an evaluating clinician.
Based on extensive clinical workup, the prodromal bvFTD group was divided into a Development Group (n = 22) and
a Validation Group (n = 50). The Development Group was selected to be the subset of the prodromal bvFTD group for
whom we had the strongest longitudinal evidence of conversion to bvFTD, and was used to develop the MBCI-FTD
criteria. The Validation Group was the remainder of the prodromal bvFTD group and was used as a separate sample
on which to validate the criteria. Familial non-carriers were included as healthy controls (n = 165). The frequencies of
behavioural and neuropsychiatric features, neuropsychological deficits, and social cognitive dysfunction in the prodromal bvFTD Development Group and healthy controls were assessed.
Based on sensitivity and specificity analyses, seven core features were identified: apathy without moderate-severe
dysphoria, behavioural disinhibition, irritability/agitation, reduced empathy/sympathy, repetitive behaviours (simple
and/or complex), joviality/gregariousness, and appetite changes/hyperorality. Supportive features include a neuropsychological profile of impaired executive function or naming with intact orientation and visuospatial skills,
reduced insight for cognitive or behavioural changes, and poor social cognition. Three core features or two core features plus one supportive feature are required for the diagnosis of possible MBCI-FTD; probable MBCI-FTD requires
imaging or biomarker evidence, or a pathogenic genetic mutation.
The proposed MBCI-FTD criteria correctly classified 95% of the prodromal bvFTD Development Group, and 74% of the
prodromal bvFTD Validation Group, with a false positive rate of 510% in healthy controls. Finally, the MBCI-FTD criteria were tested on a cohort of individuals with prodromal Alzheimer’s disease, and the false positive rate of diagnosis was 11–16%. Future research will need to refine the sensitivity and specificity of these criteria, and incorporate
emerging biomarker evidence.
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Coordinating Center; RSMS = Revised Self-Monitoring Scale; SNQ = Social Norms Questionnaire

Introduction
Detecting the earliest clinical features of neurodegenerative diseases is important for appropriate clinical trial enrolment and optimal patient care. Clinical prodromes of dementia due to
Alzheimer’s disease and dementia with Lewy bodies have been
previously defined, with published diagnostic criteria for mild cognitive impairment (MCI) due to Alzheimer’s disease,1 and prodromal dementia with Lewy bodies.2 To date, no formal criteria
have been generated for prodromal behavioural variant frontotemporal dementia (bvFTD).
Frontotemporal dementia (FTD) is the fourth most common dementia, and disproportionately affects younger individuals. The
median onset is during the sixth decade,3 though onset may be as
early as the third decade.4 Between 15–30% of all FTD cases follow

an autosomal dominant pattern of inheritance. The majority of
genetic FTD is caused by mutations in the microtubule-associated
protein tau (MAPT) or progranulin (GRN) genes, or a hexanucleotide
repeat expansion in chromosome 9 open reading frame 72
(C9orf72), though a number of other disease-causing mutations
have been decribed.5 MAPT, GRN and C9orf72 mutations are highly
penetrant.6 Carriers of autosomal dominant pathogenic mutations represent a valuable cohort for characterizing the disease
prodrome because disease onset is, to some degree, predictable,
allowing the earliest stages of disease to be tracked.7,8
Furthermore, neuropathology in genetic mutation carriers can
be predicted. Sporadic cases of bvFTD tend to come to the
attention of specialists after the prodromal phase, and require
autopsy data (neuropathological evaluation) to confirm disease
pathology.
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Early symptoms of bvFTD

The current study
To date, the earliest clinical features of bvFTD have been described
in small cohorts, but no diagnostic criteria exist. Early detection
will likely optimize treatment efficacy, and is important for early
counselling and guidance, as well as the implementation of management strategies. Parallel lines of research have described behavioural symptoms (‘mild behavioural impairment’) in
prodromal neurodegenerative diseases, not specifically FTD, and a
checklist is available21 that operationalizes the most recent mild
behavioural impairment criteria.22 However, these criteria were
not developed with bvFTD as the focus.23 Thus, the aim of the current study was to develop research diagnostic criteria for prodromal bvFTD, in a cohort of early symptomatic (‘prodromal’)
individuals carrying a MAPT, GRN, or C9orf72 pathogenic mutation
that progressed to overt bvFTD, as compared to healthy control
subjects, defined here as non-mutation carrier family members.
We then aimed to validate the criteria on a separate group, which
included pathogenic mutation carriers and/or individuals with
pathology-confirmed frontotemporal lobar degeneration (FTLD) on
autopsy, all of whom had received a clinical diagnosis indicative of
a behavioural phenotype (bvFTD or ‘mild behavioural impairment’). Finally, we tested the criteria in a group of individuals with
pathology-confirmed Alzheimer’s disease, who were seen during
their prodromal disease stage, to establish the specificity of the criteria to FTD. In these criteria, we have opted to use the term ‘mild
behavioural and/or cognitive impairment in bvFTD’ (MBCI-FTD), to
acknowledge that both behavioural/neuropsychiatric symptoms
and cognitive impairments might be present during the disease
prodrome.

Materials and methods
Study data
We used data from the Advancing Research and Treatment for
Frontotemporal Lobar Degeneration (ARTFL; U54 NS092089) and
Longitudinal Evaluation of Familial Frontotemporal Dementia
Subjects (LEFFTDS; U01 AG045390) North American consortia [now
the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar
Degeneration consortium (ALLFTD; U19 AG063911)] (January 2020

data freeze), the National Alzheimer’s Coordinating Center (NACC;
U24 AG072122), and the Examination of the Earliest Symptoms and
Biomarkers of FTLD in MAPT Carriers (ESFTLD; R01 NS076837)
study based at Columbia University. Participants in the ARTFL/
LEFFTDS studies are evaluated yearly at one of 18 sites across
North America, with a standardized clinical evaluation including a
neurological exam, neuropsychological testing, informant interviews, blood draw, brain MRI scan, and optional lumbar puncture.
Full study procedures, including genotyping of FTLD-associated
genes, have been published elsewhere.24–32 Similarly, the
Alzheimer’s Disease Research Centers (ADRCs) that contribute
data to NACC evaluate participants longitudinally and collect clinical, neuropsychological, and diagnostic data using the Uniform
Data Set (UDS). A subset of participants receive a neuropathological evaluation at autopsy. Full descriptions of NACC, UDS, and
neuropathological evaluation are available elsewhere.33–36 The
current study used data from 31 ADRCs, collected between 2005
and 2018. The ESFTLD study is a longitudinal study of families
with known pathogenic MAPT mutations, with similar assessments to ARTFL/LEFFTDS; study procedures are described elsewhere.17,37,38
The
ARTFL/LEFFTDS/ALLFTD
study,
NACC
participating ADRCs, and ESFTLD study received ethical approval,
and all participants or their surrogates provided informed written
consent.

Participant selection
Prodromal bvFTD group
To define the prodromal features of bvFTD, we selected participants from the ARTFL/LEFFTDS, ESFTLD, and NACC datasets, with
either (i) a confirmed pathogenic FTLD-associated genetic mutation as a proxy for FTLD neuropathology; or (ii) pathologically-confirmed FTLD on autopsy. All participants included in this group
were assigned a behavioural clinical phenotype (bvFTD or ‘mild behavioural impairment’) at some point during their participation in
the study; thus, those with pure or predominant primary progressive aphasia, amyotrophic lateral sclerosis, or parkinsonian syndromes were excluded. Participants were defined as ‘prodromal’
based on the clinician-assigned Clinical Dementia Rating (CDRV)
Dementia Staging Instrument plus NACC FTLD Behaviour and
Language Domains (CDRV + NACC FTLD) global score. This score is
calculated after rating impairment (0 = none, 0.5 = questionable/
very mild, 1 = mild, 2 = moderate, 3 = severe) across eight domains:
Memory, Orientation, Judgement and Problem Solving,
Community Affairs, Home and Hobbies, Personal Care,39
Behaviour, and Language.40 Domain ratings are combined using an
V
algorithm to calculate the CDR + NACC FTLD global score (0–3),28
which is sensitive to changes in early FTLD.27,40 The first visit at
which a CDRV + NACC FTLD global score of 0.5 was assigned, indicating very mild features consistent with ‘questionable’ or prodromal dementia, was considered the ‘prodromal visit’. At this
evaluation, none of the prodromal bvFTD group met Rascovsky et
al.10 criteria for bvFTD based on clinician-recorded symptoms; this
was to ensure that all participants could be validly deemed
‘prodromal’.
From the ARTFL/LEFFTDS dataset, n = 38 prodromal pathogenic
mutation carriers were included. In addition, three MAPT mutation
carriers from the Columbia University ESFTLD study and 14 genetic
mutation carriers from NACC were included, rendering a final prodromal genetic mutation carrier sample of n = 55 (MAPT = 20,
GRN = 7, C9orf72 = 17, C9orf72 + GRN = 1, unspecified mutation = 10).
From NACC, 17 participants with pathology confirmed FTLD, who
had ultimately received a clinical diagnosis of bvFTD and who
were seen by a clinician during their prodromal disease stage,
were also identified for inclusion. These participants were
R

R

R

R
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The behavioural variant is the most frequent clinical phenotype of
sporadic and genetic FTD, and is characterized by changes in behaviour, social conduct, and personality.9,10 In the most recent
bvFTD diagnostic criteria, Rascovsky et al.10 specify that the earliest
symptoms (presenting within the first 3 years of the illness) include apathy, behavioural disinhibition, loss of sympathy or empathy, and perseverative behaviours. Likewise, in genetic
mutation carriers destined to develop FTD, apathy and disinhibition are reported to be among the first behavioural symptoms.11,12
Psychotic symptoms, such as hallucinations and delusional
beliefs, have also been reported in the years prior to diagnosis, particularly in C9orf72 expansion carriers.13–15
The neuropsychological profile of bvFTD tends to be dysexecutive (i.e. deficits in higher-order cognitive skills such as reasoning,
planning, abstraction, word generation), with relative preservation
of episodic memory and visuospatial functions.10,16 However, early
changes have been documented in the domains of language, attention, memory, and social cognition, as well as executive function.7,8,11,17–19
Informantand
patient-reported
memory
complaints are also common in preclinical bvFTD.11,20 Cognitive
changes may precede behavioural symptoms in a subset of
patients who go on to develop bvFTD.19
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Healthy control group
Healthy control participants were defined as familial non-carriers
(participants with a known FTLD-associated genetic mutation in
the family but who were not carriers themselves). Healthy controls
were drawn from the ARTFL/LEFFTDS dataset (n = 165), because
this study had the most comprehensive assessments available.
Healthy controls were older than 30 years, to match the prodromal
bvFTD group in age (Supplementary Fig. 1).

Alzheimer’s Test Group
A cohort of n = 301 individuals with pathology-confirmed
Alzheimer’s disease were drawn from the NACC dataset. All participants were evaluated by a clinician during their prodromal disease phase, at which point they received a global CDRV of 0.5 and a
diagnosis of MCI due to presumed Alzheimer’s disease (47% single-domain amnestic MCI, 47% multiple-domain amnestic MCI,
6% non-amnestic MCI). On autopsy, all individuals in this group
had intermediate or high Alzheimer disease neuropathological
changes based on NIA-AA criteria,41,42 and 38% had evidence
of Lewy body pathology [5% brainstem-predominant, 22%
limbic (transitional) or amygdala predominant, 11% neocortical
(diffuse)].
R

Measures
Behavioural and neuropsychiatric features
Participants underwent detailed clinical evaluation, and additional
measures were obtained via interview with informants.
Assessments included the NACC UDS and FTLD module.43 All clinicians, study personnel, patients, and informants were blind to
study aims at the time of the evaluations.
Standard clinician forms
The clinician forms included the following features to be evaluated: apathy/withdrawal/inertia, depressed mood, psychosis (visual/auditory hallucinations, abnormal/false/delusional beliefs),
behavioural disinhibition, irritability, agitation, personality
change, REM sleep behaviour disorder, anxiety, hyperorality, loss
of sympathy or empathy, and ritualistic or compulsive behaviours.
All features were marked as present or absent by the clinician at
the evaluation.
Behavioural/neuropsychiatric questionnaires
The Neuropsychiatric Inventory Questionnaire (NPI-Q)44 was completed with the informant and includes the following items: apathy/
indifference, depression/dysphoria, delusions, hallucinations, disinhibition, irritability/lability, agitation/aggression, anxiety, night
time behaviours, elation/euphoria, motor disturbance, and appetite/eating changes. All features were marked as present (mild,
moderate or severe) or absent. The 15-item version of the Geriatric
Depression Scale (GDS),45 a measure of depressive symptoms,

especially dysphoria, was administered to participants. The
Interpersonal Reactivity Index46 (Empathic Concern and Perspective
Taking subscales) was included as a measure of informant-reported
empathy.
Clinical notes
A goal of the study was to capture features that are beyond the
scope of the current bvFTD diagnostic criteria. In the ARTFL/
LEFFTDS dataset, the richest source of this information was free
text clinical notes [e.g. Clinical Global Impressions of Change form
(CGI-C)]. The CGI-C is a structured interview such that the patient
and the informant answer the same questions regarding behavioural and cognitive changes.47 Clinical notes were available for 26
participants from the prodromal bvFTD group. Each study site that
contributed participants to the prodromal bvFTD group provided
at least one CGI-C clinical note. Based on the most frequently
endorsed features in these notes, as well as the bvFTD literature,
the following features were extracted: apathy, disinhibition, irritability, loss of empathy/sympathy, repetitive behaviours [simple
(e.g. pacing) and complex (e.g. rituals)], hyperorality, depression,
sleep problems, joviality/gregariousness, delusions, hallucinations, emotional blunting, and reduced insight. Features were considered ‘present’ if they were reported by the informant, subject,
or clinician. Reduced insight was marked as ‘present’ if the informant reported behavioural or cognitive problems that were not
endorsed by the patient. Retrospective coding of the free text clinical notes was completed by two independent raters (M.S.B and
R.T.G), with an interrater reliability of 0.89; disagreements were
adjudicated by a third rater (M.M.). Raters were not blind to study
objectives, but were instructed to be comprehensive in identifying
features noted in the free text, with little a priori guidance as to the
specific features themselves. The goal was to identify features that
may be missed on the standardized clinician and informant forms,
which only capture a relatively narrow range of symptoms.

Neuropsychological assessment
All participants completed a standardized neuropsychological assessment (NACC UDS v. 1.1, 1.2, 2.0 or 3.0 batteries).33–35,43 The
Craft Story or Logical Memory immediate and delayed recall scores
measured verbal episodic memory. The Benson Complex Figure
copy and delayed recall assessed visuospatial skills and non-verbal episodic memory, respectively. The Montreal Cognitive
Assessment (MoCA)48 cube drawing or Mini-Mental State
Examination (MMSE) pentagon drawing tests49 assessed visuospatial skills when the Benson Figure copy was not available. The
Multilingual Naming Test (MINT) or Boston Naming Test (BNT, 30item odd) measured visual confrontation naming. The Digit or
Number Span Forward and Backward tests gauged auditory attention and working memory, respectively. Verbal initiation and generation were measured with verbal fluency tasks, with both
category (animals) and letter (F, L) cues. Trail Making A measured
psychomotor speed, and Trail Making B assessed set-shifting, a
facet of executive function. The MoCA or MMSE provided a brief
global assessment of cognition.

Social cognition assessment
Questionnaires from the NACC FTLD module assessing social cognition were administered to all ARTFL/LEFFTDS and Columbia
ESFTLD study participants. The Social Norms Questionnaire (SNQ),
which gauges awareness of social expectations,50 was completed
by the participant. Two types of errors can be made on the SNQ:
breaking a social norm (‘break score’, e.g. saying it is okay to eat
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presumed to be sporadic, as no known genetic mutation was
recorded. In total, the prodromal bvFTD sample was n = 72 (see
Supplementary Fig. 1 for full details). Staff evaluating the participants were blinded to genetic status whenever possible. This was
not always possible if the participant was referred from a clinical
setting in which they had been evaluated by a member of the research team, or if the research participant self-disclosed. In these
cases, effort was taken to preserve the blinding of other staff
members.
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pasta with your fingers) and over-adhering to social norms (‘overadhere score’, e.g. saying it is not okay to eat ribs with your fingers). The SNQ is based on mainstream North American culture.
The Revised Self-Monitoring Scale (RSMS), a questionnaire that
measures socioemotional sensitivity,51 was completed by the
informant.

We aimed to first develop a set of criteria, and then validate and
test the proposed criteria. Thus, the study was broadly separated
into a development phase and a validation and testing phase.
Subsets of the prodromal bvFTD and healthy control groups were
included in both the development and validation phases, while
the Alzheimer’s cohort was used only in the testing phase.

Prodromal bvFTD Development Group and
Validation Group
In order to develop and validate the MBCI-FTD criteria, we divided
the prodromal bvFTD cohort (n = 72) into a Development Group
(n = 22) and a Validation Group (n = 50) (Fig. 1). The purpose of creating these groups was to define a cohort to use to develop the criteria (Development Group) in which we had the highest
confidence that the features observed and reported were part of a
bvFTD prodrome, and a separate more heterogeneous cohort on
which to validate the criteria (Validation Group). All participants
included in the Development Group showed clear longitudinal disease progression towards bvFTD (clinical details are provided in
Supplementary Table 1). In brief, the Development Group included
participants with all of the following: (i) at least one follow-up visit
subsequent to their prodromal visit; (ii) evidence of disease progression following their prodromal visit, as measured by an increase in the CDRV + NACC FTLD Sum of Boxes score; (iii) an
increase over time in behavioural symptoms consistent with
bvFTD; and (iv) a minimum of three Rascovsky et al.10 BvFTD diagnostic criteria features present at their most recent study visit, two
of which had to be predominant features of the clinical presentation. Participants from NACC were not included in the
Development Group as the available measures were more limited
(see Supplementary Table 2 for the specific assessment measures
available in each study, and for the n’s drawn from each study).
The final Development Group included n = 22 prodromal bvFTD
participants from the ARTFL/LEFFTDS and Columbia ESFTLD studies (MAPT = 12, GRN = 2, C9orf72 = 7, C9orf72 + GRN = 1; Fig. 1).
The Validation Group included: (i) the remainder of the prodromal bvFTD group from ARTFL/LEFFTDS who (a) only had a single study visit; or (b) had multiple study visits, but the evaluation
at follow-up visits did not meet behavioural criteria for the
Development Group (i.e. clinician indicated a bvFTD phenotype
but explicit documentation of the Rascovsky et al.10 diagnostic criteria was not available); or (ii) participants drawn from the NACC
dataset. The inclusion of the Validation Group as an independent
(i.e. no overlapping subjects) validation sample was based on the
assumption that the vast majority would go on to meet full
Rascovsky et al.10 diagnostic criteria for bvFTD at some point during their disease course, but with less certainty than the
Development Group. The final Validation Group included n = 50
prodromal bvFTD participants from ARTFL/LEFFTDS and NACC
(MAPT = 8, GRN = 5, C9orf72 = 10, unspecified mutation = 10, presumed sporadic = 17; Fig. 1).
R

Development phase
Half of the healthy control group was randomly selected as a comparison for the prodromal bvFTD Development Group, to be used
in developing the criteria (Healthy Control Group 1; n = 82) (Fig. 1).
From the clinician forms, informant forms, and clinical notes, a
list of potential behavioural or neuropsychiatric features was created: apathy/withdrawal/indifference, disinhibition, irritability/lability, agitation, reduced empathy or sympathy, depression,
anxiety, psychosis (delusions or hallucinations), repetitive behaviours, sleep disturbances, elation/euphoria, appetite changes/
hyperorality, joviality/gregariousness, reduced insight, and emotional blunting. All features were either ‘present’ or ‘absent’ per
clinician or informant rating. In the case of the Interpersonal
Reactivity Index, reduced empathy was considered ‘present’ if the
participant was rated 5 1.5 standard deviations (SD) below ageand sex-specific means (see Supplementary Table 3 for cut-off
scores). In constructing this list, the following a priori decisions
were made: (i) apathy was only considered present if there was no
evidence of moderate-severe dysphoria as reported on the GDS
(46/15), to allow the MBCI-FTD criteria to distinguish between
major depressive disorder and bvFTD; (ii) informant-reported irritability was included in analyses if it reached a moderate level, to
maximize specificity against neurologically healthy controls in
whom mild irritability is common (this decision was supported
post hoc by the clinical notes in which examples of moderate-severe irritability and labile mood were frequent); and (iii) personality change was excluded from current analyses as its definition
was determined to be too broad to be useful in the context of criteria (decided by clinical consensus).
Impairments on neuropsychological tests were coded as ‘present’ or ‘absent’ based on non-linear age-, sex- and educationadjusted z-scores,26 and impairment was defined as z 4 –1.5. With
regard to the social cognition assessment, the questionnaires are
designed to have substantial variability in performance below the
normal range; thus, Youden’s J index was calculated to identify optimal cut-off scores that would discriminate between the prodromal bvFTD and control groups. Impairment was defined as
performance below the Youden cut-off (Supplementary Fig. 2).

Validation and testing phase
Once a set of criteria had been developed, we aimed to establish
their utility, by testing whether they were able to correctly classify
a separate cohort of prodromal bvFTD participants (Validation
Group), and healthy controls (Healthy Control Group 2; n = 83), as
well as a cohort of individuals with prodromal Alzheimer’s disease
(Alzheimer’s Test Group; n = 301). The Validation Group of prodromal bvFTD participants allowed us to determine whether the
criteria were generalizable to a more heterogenous prodromal
bvFTD cohort, including presumably sporadic cases. Testing the
criteria in the healthy controls and prodromal Alzheimer’s disease
allowed us to determine whether the criteria would correctly classify non-FTD individuals.

Statistical analyses
All statistical analyses were performed using JASP version 0.11.1.0
or custom scripts in Python version 3.6. Analyses conducted to establish the criteria used data from the prodromal bvFTD
Development Group and Healthy Control Group 1 only. Analyses
conducted to validate and test the criteria used data from the prodromal bvFTD Validation Group, Healthy Control Group 2, and the
Alzheimer’s Test Group only.
To assess whether the prodromal bvFTD Development Group
was demographically different from Healthy Control Group 1 (used
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in the development phase of the criteria) and from the prodromal
bvFTD Validation Group, we conducted two-tailed independent
groups t-tests to compare age, education, and disease severity (as
measured by the CDRV + NACC FTLD Sum of Boxes, where applicable), and two-proportions z-tests to compare sex and handedness
(a = 0.05).
All candidate features, including behavioural/neuropsychiatric
features, neuropsychological impairments, and social cognition
impairments, were dichotomous (present versus absent). We calculated sensitivity and specificity for each feature using 2  2
matrices. Sensitivity is the proportion of the prodromal bvFTD
group who had the feature present [sensitivity = true positives /
(true positives + false negatives)]. Specificity is the proportion of
healthy controls who did not display the feature [specificity = true
negatives / (true negatives + false positives)]. Confidence intervals
(95% CI) are reported.
Finally, sensitivity and specificity were calculated for the criteria as a whole, first on the Development Group and Healthy
Control Group 1, and then on the Validation Group, Healthy
Control Group 2, and the Alzheimer’s Test Group.
R

Data availability
ARTFL/LEFFTDS data are available upon request from the ALLFTD
Executive Committee at https://www.allftd.org/. Columbia ESFTLD
study data are available upon request from the corresponding author (E.D.H). NACC data are available upon request at https://nacc
data.org/. Sensitive genetic information prevents public archiving
of the ARTFL/LEFFTDS and ESFTLD datasets.

participants and healthy control subjects, and 92% of the
Alzheimer’s Test Group, self-identified as white/Caucasian.

Development versus Validation Group
Statistical comparisons were conducted to assess demographic
differences between the prodromal bvFTD Development and
Validation Groups (Table 2). The groups appeared similarly distributed with respect to age, education, and disease severity (per
CDRV + NACC FTLD Sum of Boxes). The balance of males to females
appeared consistent across groups (0.45 versus 0.68), as did handedness (0.91 versus 0.85). There was a statistically significant
higher proportion of MAPT mutation carriers in the Development
Group than the Validation Group (0.55 versus 0.16); this is
addressed in the ‘Validation and testing phase’ results section.
R

Development Group versus Healthy Control Group 1
As the two groups involved in the development of the criteria, statistical comparisons were conducted to test for demographic differences between the Development Group and Healthy Control Group
1 (Table 2). The groups appeared similarly distributed in education.
The Development Group was estimated to be slightly older, P =
0.020, but this difference of 7 years (56 versus 49 years) was not
considered clinically meaningful. The sex balance was reasonably
consistent across groups (0.45 versus 0.36), as was handedness
(0.91 versus 0.84).

Development phase
Behavioural and neuropsychiatric features

Results
Demographic information
All prodromal bvFTD participants and healthy controls were 31–
80 years old; group means spanned 49–56 years (Table 1). The
Alzheimer’s Test Group was older on average (mean = 80.5 years),
as would be expected. All groups were highly educated on average
(15–16 years of education). Over 97% of prodromal bvFTD

Table 3 presents the frequencies, as well as sensitivity and specificity, of the behavioural and neuropsychiatric features in the prodromal bvFTD Development Group, reported on the clinician and
informant forms (n = 22), and frequencies of the features extracted
from the clinical notes [available for 68% (n = 15) of the
Development Group]. The most frequent clinician-rated features
were apathy (59%), disinhibition (55%), irritability (41%), and
reduced empathy/sympathy (50%). Likewise, apathy (64%),
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Figure 1 Schematic depicting data used in the development and validation/testing phases of the study. Grey shaded boxes represent the participants
included in the development phase, unshaded boxes represent the participants included in the validation and testing phase. The prodromal bvFTD
participants were assigned to the Development Group based on longitudinal evidence of disease progression and strong evidence of phenoconversion to bvFTD (see ‘Materials and methods’ section). Healthy controls were randomly assigned to Healthy Control Group 1 and Healthy Control
Group 2. *ARTFL/LEFFTDS study data. ˆColumbia ESFTLD study data. #NACC data. The prodromal bvFTD Development Group included one additional
participant not depicted in the subgroups of the figure, who carries both a GRN mutation and a C9orf72 repeat expansion.
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Table 1 Demographic and clinical characteristics of the prodromal bvFTD group (including Development and Validation Groups),
healthy controls (Healthy Control Groups 1 and 2), and the Alzheimer’s Test Group
Total prodromal
bvFTD group
(n = 72)

Validation
Group
(n = 50)

Healthy Control
Group 1
(n = 82)

Healthy Control
Group 2
(n = 83)

Alzheimer’s Test
Group
(n = 301)

12 (55%)
2 (9%)
7 (32%)
1 (5%)
0 (0%)

8 (16%)
5 (10%)
10 (20%)
0 (0%)
10 (20%)

N/A

N/A

N/A

0 (0%)

17 (34%)

56.18 (11.17)
36–80

56.68 (11.48)
32–76

49.41 (12.09)
31–80

51.59 (11.08)
32–76

80.49 (9.87)
35–100

15.23 (2.41)
12–20
10:12
20:2:0

15.06 (2.27)
12–21
34:16
42:7:1

15.07 (2.55)
11–20
30:52
69:9:3b

16.02 (2.40)
12–20
38:45
71:8:4

15.94 (3.06)a
2–25
152:149
268:24:8b

1.89 (0.87)
0.5–3.5

2.05 (0.98)
0.5–3.5

0.16 (0.52)
0.0–3.0

0.07 (0.37)
0.0–3.0

1.43 (0.93)c
0.5–4.5c

R

R
V

Age and education are reported in years. Genetic status refers to FTLD-associated genetic mutations. CDR + NACC FTLD Sum of Boxes score calculated by summing the six
V
CDR domain rating scores, plus two supplemental domains of behaviour and language. M = male; F = female, self-reported. R = right-handed; L = left-handed; A =
R

ambidextrous.
a

Education values missing for three participants in the Alzheimer’s Test Group.

b
c

R
V

R
V

Traditional CDR sum of boxes score, calculated by summing only the six CDR domain rating scores, appropriate for Alzheimer’s disease.
Handedness was unknown for one healthy control and one participant in the Alzheimer’s Test Group.

Table 2 Statistical comparisons of demographic and clinical characteristics in the prodromal bvFTD Development and Validation
Groups, and Healthy Control Group 1

Development Group versus Validation Group
Age
Education
Sex
Handedness
V
CDR + NACC FTLD Sum of Boxes
Proportion of MAPT mutation carriers
Development Group versus Healthy Control Group 1
Age
Education
Sex
Handedness
R

Mean difference

95% CI Lower, upper

P-value

–0.50
0.17
–0.23
0.07
–0.16
0.28

–6.31, 5.31
–1.01, 1.35
–0.50, 0.05
–0.12, 0.26
–0.65, 0.32
0.12, 0.65

0.865
0.778
0.122
0.681
0.501
0.002

6.77
0.15
0.09
0.07

1.10, 12.44
–1.05, 1.34
–0.17, 0.35
–0.10, 0.24

0.020
0.800
0.608
0.645

Italic text denotes statistically significantly difference between groups at a = 0.05. Development Group comprised n = 22 prodromal bvFTD participants, Validation Group comprised n = 50 prodromal bvFTD participants, Healthy Control Group 1 comprised n = 82 familial non-carrier controls.

disinhibition (55%), irritability (64%), and reduced empathy/sympathy (50%), were the most frequent informant-endorsed features.
Agitation was endorsed similarly highly by informants (55%), but
in only 5% of cases by clinicians. This may be due to differences in
how the question is worded; the clinician form defines agitation as
‘trouble sitting still’ and/or ‘shouting/kicking/hitting’, while the informant form asks about being ‘hard to handle’ or ‘resistive to
help’. In addition, agitation might present differently in home versus clinical settings, clinicians and caregivers may differently classify a given behaviour (e.g. if a patient becomes agitated if stopped
from performing a repetitive behaviour), or clinicians may have a
higher threshold of what constitutes agitation. In the clinical

notes, apathy and disinhibition were endorsed in two-thirds of the
Development Group, and irritability in one-third. Overall, when
combining clinician and informant reports, apathy, disinhibition,
irritability, and reduced empathy/sympathy had good sensitivity
and specificity, with each reported in 570% of the prodromal
bvFTD Development Group and 413% of healthy control subjects
(Table 3).
Results were less clear for mood symptoms. Depression was
moderately endorsed by clinicians (23%) and informants (41%), but
self-reported depressed mood/dysphoria was minimal (GDS). In
fact, the GDS mean was 2.8/15 (SD = 2.95), with only one individual
from the prodromal bvFTD Development Group scoring 46, and
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Genetic status, n (%)
MAPT
20 (28%)
GRN
7 (10%)
C9orf72
17 (24%)
C9orf72 + GRN
1 (1%)
Unspecified
10 (14%)
mutation
Presumed sporadic
17 (24%)
Age
Mean (SD)
56.53 (11.31)
Range
32–80
Education
Mean (SD)
15.11 (2.30)
Range
12–21
Sex (M:F)
44:28
Handedness (R:L:A)
62:9:1
V
CDR + NACC FTLD Sum of Boxes
Mean (SD)
2.00 (0.94)
Range
0.5–3.5

Development
Group
(n = 22)
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Table 3 Behavioural and neuropsychiatric features of the prodromal bvFTD Development Group and Healthy Control Group 1
Specificity
[95% CI]

18 (82%)

0.82 [0.60, 0.95]

0.94 [0.86, 0.98]

10 (67%)
5 (33%)
N/A
7 (47%)
0 (0%)
1 (7%)
3 (20%)

18 (82%)
16 (73%)
13 (59%)
16 (73%)
10 (45%)
10 (45%)
3 (14%)

0.82 [0.60, 0.95]
0.73 [0.50, 0.89]
0.59 [0.36, 0.79]
0.73 [0.50, 0.89]
0.45 [0.24, 0.68]
0.45 [0.24, 0.68]
0.14 [0.03, 0.35]

0.91 [0.83, 0.96]
0.90 [0.82, 0.96]
0.93 [0.85, 0.97]
0.88 [0.79, 0.94]
0.69 [0.58, 0.79]
0.74 [0.64, 0.83]
0.99 [0.93, 1.00]

4 (18%)

3 (20%)

8 (36%)

0.36 [0.17, 0.59]

0.95 [0.88. 0.99]

0 (0%)

8 (36%)

1 (6%)

8 (36%)

0.36 [0.17, 0.59]

0.72 [0.61, 0.81]

N/A
1 (5%)
N/A
N/A
N/A

5 (23%)
8 (36%)
N/A
N/A
N/A

N/A
2 (13%)
7 (47%)
9 (60%)
1 (7%)

5 (23%)
9 (41%)
7/15a (47%)
9/15a (60%)
1/15a (7%)

0.23 [0.08, 0.45]
0.41 [0.21, 0.64]
0.47 [0.21, 0.73]
0.60 [0.32, 0.84]
0.07 [0.00, 0.32]

0.98 [0.91, 1.00]
0.91 [0.83, 0.96]
N/A
N/A
N/A

Informant
report
n = 22

13 (59%)

14 (64%)

10 (67%)

12 (55%)
9 (41%)
1 (5%)
11 (50%)
5 (23%)
2 (9%)
3 (14%)

12 (55%)
14 (64%)
12 (55%)
11 (50%)
9 (41%)
10 (45%)
2 (9%)

4 (18%)

Total number in
Development
Group with feature n = 22

Feature may be endorsed by clinician, informant or patient to be included in the ‘Total’ column. ‘Without dysphoria’ refers to a lack of moderate-to-severe dysphoria per selfreport on the GDS. CI = confidence interval, binomial calculation, lower and upper bounds shown. Prodromal bvFTD Development Group comprised n = 22 with clinician and
informant report data (MAPT = 12, GRN = 2, C9orf72 = 7, C9orf72 + GRN = 1) and n = 15 with clinical notes (MAPT = 10, GRN = 1, C9orf72 = 3, C9orf72 + GRN = 1). Informant report
was based on the Neuropsychiatric Inventory Questionnaire (NPI-Q) except in the case of empathy/sympathy, which was based on the Interpersonal Reactivity Index (IRI) total
score; sensitivity and specificity for the IRI subscale scores are: Empathic Concern = 0.27, 0.89; Perspective Taking = 0.45, 0.93. Clinical notes were based on both patient and informant report, as well as clinical impression. Specificity calculated in Healthy Control Group 1, n = 82. N/A = not available.
a

Clinical notes are the only source of information for this feature, n = 15.

two scoring 6, commensurate with mild depression.45 Notably,
reports of depressed mood were absent from all free text clinical
notes. Anxiety was moderately commonly endorsed by informants
(45%), but clinician endorsement was only 9%, and was only mentioned in one clinical note. These discrepancies highlight the difficulty in parsing out neuropsychiatric features; for example, a
patient who is pacing might be seen as anxious by family members
despite denying feelings of anxiety, or an apathetic patient who
watches television all day may be described as depressed by family
members but is not experiencing dysphoria. Since anxiety and depression had low specificity, with symptoms reported in 25–30% of
healthy controls, we decided that these features did not adequately discriminate between the groups.
Other features present in the Development Group included appetite changes or hyperorality (41%), elation/euphoria (23%), and
repetitive behaviours (simple, e.g. pacing; or complex, e.g. ritualistic behaviours) (36%). Although sensitivity was lower than other
features, specificity was excellent, with each feature present in
510% of healthy controls. Night time behaviours (e.g. awakening
during night) were noted relatively frequently by informants and
in the clinical notes (36%); REM sleep behaviour disorder was not
noted in any of the participants. However, night time behaviours
had poor specificity, occurring in 28% of control subjects. Contrary
to expectations,52 psychosis was rare in our sample.
Hallucinations were reported in only two participants in the prodromal bvFTD Development Group (9%), and those same two participants plus one other reported delusions (14%) (n = 2 MAPT, n =
1 C9orf72).
Several additional features were extracted from the clinical
notes: reduced insight, joviality/gregariousness, and emotional
blunting. Interestingly, reduced insight was present in 60% of the
group for whom we had clinical notes, which was almost as frequent as reports of apathy and disinhibition in the clinical notes

(Table 3). Joviality/gregariousness was endorsed in 47%. Emotional
blunting was only noted in one individual. Specificity analyses
could not be conducted on these data as clinical notes were not
available for healthy controls. However, due to the value and richness of this information, we opted to include these data to ensure
we were not missing any features that would optimize the sensitivity of the criteria.

Neuropsychological assessment
Table 4 presents the neuropsychological deficits in the prodromal
bvFTD Development Group. Executive dysfunction was defined as
clinical impairment (z 4 –1.5) on either Trails B time or Letter fluency, or 52 errors on Trails B.53 This was the most common domain of impairment, occurring in 50% of the Development Group.
The second most frequent impairment was in naming, which was
present in 45%. Semantic generation impairments (animal fluency)
were present in 41% of the Development Group. Episodic memory
impairments (delayed free recall) were present more frequently in
the verbal domain (36%) than the non-verbal domain (18%).
Psychomotor speed was clinically slowed in 36% of the
Development Group. Simple auditory attention was intact in the
majority (impairments in 9%), while working memory impairments were present in 23%. Interestingly, 23% of the prodromal
bvFTD Development Group scored below the clinical z-score cutoff in the visuospatial domain, but inspection of the raw scores
revealed that no one scored less than 13/17, indicating that visuospatial skills were largely preserved. Orientation remained intact
(55/6) in everyone in the prodromal bvFTD Development Group.

Social cognition assessment
For the SNQ, a Break score of 52 and an over-adhere score of 53
optimally discriminated between the groups. An optimal cut-off of
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Apathy/withdrawal/indifference without dysphoria
Disinhibition
Irritability/lability
Agitation
Reduced empathy or sympathy
Depression
Anxiety
Psychosis (delusions +
hallucinations)
Repetitive behaviours (simple
+ complex)
REM sleep disorder/night time
behaviours
Elation/euphoria
Appetite changes/hyperorality
Joviality/gregariousness
Reduced insight
Emotional blunting

Sensitivity
[95% CI]

Clinical
notes
n = 15

Clinician
indicated
n = 22
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Table 4 Neuropsychological characteristics of the prodromal bvFTD Development Group and Healthy Control Group 1
Cognitive domain

Executive function

Nonverbal episodic
memory
Psychomotor speed
Orientation

Trails B time, Trails B errors,
letter fluency (F, L)
MINT or BNT
Category fluency (animals)
Number span forward
Number span backward
Benson Figure copy
Craft Story or Logical Memory
delayed recall
Benson Figure delayed recall
Trails A
MoCA orientation

Number in Development
Group with impairment n = 22

Sensitivity
[95% CI]

Specificity
[95% CI]

11 (50%)

0.50 [0.28, 0.72]

0.74 [0.64, 0.83]

10 (45%)
9 (41%)
2 (9%)
5 (23%)
5 (23%)
8 (36%)

0.45 [0.24, 0.68]
0.41 [0.21, 0.64]
0.09 [0.01, 0.29]
0.23 [0.08, 0.45]
0.23 [0.08, 0.45]
0.36 [0.17, 0.59]

0.79 [0.69, 0.87]
0.91 [0.83, 0.96]
0.95 [0.88, 0.99]
0.88 [0.79, 0.94]
0.93 [0.85, 0.97]
0.86 [0.77, 0.93]

4 (18%)

0.18 [0.05, 0.40]

0.88 [0.79, 0.94]

8 (36%)
0 (0%)

0.36 [0.17, 0.59]
0.0 [0.0, 0.15]a

0.86 [0.77, 0.93]
1.0 [0.96, 1.0]a

Impairment defined as at least 1.5 SD below mean (z 4 –1.5), based on age-, sex- and education adjusted norms.26 Exceptions include: Trails B errors where impairment was
defined as 52 errors; orientation where impairment was defined as 55/6 on MoCA orientation questions. CI = confidence interval, binomial calculation, lower and upper
bounds shown. Development Group comprised n = 22 prodromal bvFTD participants (MAPT = 12, GRN = 2, C9orf72 = 7, C9orf72 + GRN = 1). Specificity calculated in Healthy
Control Group 1, n = 82. BNT = Boston Naming Test; MINT = Multilingual Naming Test.
a

One-sided 97.5% CI.

Table 5 Social cognition questionnaire results in the prodromal bvFTD Development Group and Healthy Control Group 1

SNQ
Break score (52)
Over-adhere score (53)
RSMS Total (436)

Number in Development
Group with impairment
n = 22

Sensitivity
[95% CI]

Specificity
[95% CI]

Youden’s J

6 (27%)
12 (54%)
12/20a (60%)

0.27 [0.11, 0.50]
0.54 [0.32, 0.76]
0.60 [0.36, 0.81]

0.96 [0.90, 0.99]
0.76 [0.65, 0.84]
0.86 [0.76, 0.93]

0.235
0.292
0.495

Impairment defined based on Youden cut-off. CI = confidence interval, binomial calculation, lower and upper bounds shown. Development Group comprised n = 22 prodromal
bvFTD participants (MAPT = 12, GRN = 2, C9orf72 = 7, C9orf72 + GRN = 1). Specificity calculated in Healthy Control Group 1, n = 82.
a

n = 20 from the Development Group had RSMS data (MAPT = 12, GRN = 2, C9orf72 = 5, C9orf72 + GRN = 1).

436 was identified for the RSMS, which is largely consistent with
scores obtained in known bvFTD cohorts.54
SNQ over-adhere errors were more frequent than break errors
in the Development Group (54% and 27%, respectively). However,
break errors had much higher specificity (0.96) than over-adhere
errors (0.76) (Table 5). The RSMS was frequently below the Youden
cut-off in the prodromal bvFTD Development Group (60%), and
specificity was reasonable (0.86).

Creating the MBCI-FTD criteria from the
development phase
In creating the MBCI-FTD criteria, we prioritized specificity over
sensitivity, because we aimed to develop a diagnostic tool rather
than a screening test. Thus, for inclusion as a core feature of the
criteria, specificity was required to be 40.85. We also required the
feature to be present in at least 30% (sensitivity 50.3); any feature
less frequent was considered to potentially lack clinical utility.
Several behavioural/neuropsychiatric features met these requirements and were included as core features: apathy without dysphoria, disinhibition, irritability/lability, loss of empathy/
sympathy, repetitive behaviours, joviality/gregariousness, and appetite changes. Agitation was combined with irritability for parsimony. Similarly, informant-reported elation/euphoria was
combined with joviality/gregariousness, because the questionnaire asks about acting excessively happy, similar to the clinical
reports of joviality. Table 6 provides final sensitivity and specificity
values for each feature.

With regard to the neuropsychological profile, from a clinical
utility perspective, we were interested in finding the profile that
was characteristic of the Development Group. The most frequent
impairments were in executive function and naming (50%). This
is consistent with existing literature, including sporadic cases.10,19
However, executive function and naming deficits were also present
in 21–26% of healthy controls, indicating low specificity. Therefore,
this neuropsychological profile was included as a supportive feature
rather than a core feature. In line with bvFTD diagnostic criteria,10
visuospatial skills appeared intact in the Development Group.
Everyone in the prodromal bvFTD Development Group also had intact time/place orientation. Thus, the deficit in executive function
and/or naming needs to be in the context of relatively preserved
orientation and visuospatial skills to fit the MBCI-FTD neuropsychological profile criterion (sensitivity = 0.73, specificity = 0.60; Table 6).
Despite reasonable sensitivity and specificity, impairments on
animal fluency, verbal episodic memory, and psychomotor speed
were not included in the MBCI-FTD criteria, due to poor specificity
against other neurodegenerative diseases. Category fluency and
episodic memory are compromised in early Alzheimer’s disease
dementia,55–57 while psychomotor speed problems are characteristic of dementia with Lewy bodies. We also note that the semantic
and verbal episodic memory weaknesses present in the prodromal
bvFTD Development Group may be inflated due to an overrepresentation of MAPT mutation carriers in this group.18,58,59
In terms of social cognition, both the SNQ break score (52) and
RSMS total score (436) had reasonably high specificity (40.85).
These were combined into an ‘impaired social cognition’ criterion,
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Naming
Semantic generation
Attention
Working memory
Visuospatial skills
Verbal episodic memory

Neuropsychological
tests used
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Table 6 Evaluation of the MBCI-FTD features in the prodromal bvFTD Development and Validation Groups and healthy controls
Criteria development
Number in
Development Group
with feature n = 22

Sensitivity
[95% CI]

Specificity
[95% CI]

18 (82%)
18 (82%)
17 (77%)
16 (73%)
8 (36%)

0.82 [0.60, 0.95]
0.82 [0.60, 0.95]
0.77 [0.55, 0.92]
0.73 [0.50, 0.89]
0.36 [0.17, 0.59]

0.94 [0.86, 0.98]
0.91 [0.83, 0.96]
0.87 [0.77, 0.93]
0.88 [0.79, 0.94]
0.95 [0.88. 0.99]

10 (45%)
9 (41%)

0.45 [0.24, 0.68]
0.41 [0.21, 0.64]

16 (73%)
9/15a (60%)
13 (59%)
21 (95%)

0.73 [0.50, 0.89]
0.60 [0.32, 0.84]
0.59 [0.36, 0.79]
0.95 [0.77, 1.00]

Number in
Validation Group
with feature n = 50

Sensitivity
[95% CI]

Specificity
[95% CI]

27 (54%)
26 (52%)
26 (52%)
17 (34%)
16 (32%)

0.54 [0.39, 0.68]
0.52 [0.37, 0.66]
0.52 [0.37, 0.66]
0.34 [0.21, 0.49]
0.32 [0.20, 0.47]

0.97 [0.91, 0.99]
0.95 [0.88, 0.99]
0.91 [0.83, 0.96]
0.84 [0.75, 0.91]
0.94 [0.86, 0.98]

0.98 [0.91, 1.00]
0.91 [0.83, 0.96]

11 (22%)
20 (40%)

0.22 [0.12, 0.36]
0.40 [0.26, 0.55]

1.00 [0.96, 1.0]a
0.94 [0.86, 0.98]

0.60 [0.48, 0.70]
N/A
0.87 [0.77, 0.93]
0.90 [0.82, 0.96]

20 (40%)
8/11b (73%)
9/23c (39%)
37 (74%)

0.40 [0.26, 0.55]
0.73 [0.39, 0.94]
0.39 [0.20, 0.61]
0.74 [0.60, 0.85]

0.75 [0.64, 0.84]
N/A
0.81 [0.70, 0.88]
0.93 [0.85, 0.97]

Features defined as per development phase. Development Group comprised n = 22 prodromal bvFTD participants (MAPT = 12, GRN = 2, C9orf72 = 7, C9orf72 + GRN = 1),
Validation Group comprised n = 50 prodromal bvFTD participants (MAPT = 8, GRN = 5, C9orf72 = 10, unspecified mutation = 10, presumed sporadic = 17). Specificity calculated in
Healthy Control Group 1 (n = 82) for criteria development, and Healthy Control Group 2 for criteria validation (n = 83). CI = confidence interval, binomial calculation, upper and
lower bounds shown. n = 2 participants in the Development Group were aged 70 + years at the time of their prodromal visit; with these participants excluded, the overall
results did not change [sensitivity = 0.95 (19/20)]. n = 10 participants in the Validation Group were aged 70 + years at the time of their prodromal visit; with these participants
excluded, the overall results did not meaningfully change [sensitivity = 0.75 (30/40)]. N/A = not available.
a

One-sided 97.5% CI.

b

Insight measure available for n = 15 participants in the Development Group (MAPT = 10, GRN = 1, C9orf72 = 3, C9orf72 + GRN = 1) and n = 11 participants in the Validation Group
(MAPT = 4, GRN = 3, C9orf72 = 4).
c

Social cognition assessed in n = 23 participants in the Validation Group (MAPT = 8, GRN = 5, C9orf72 = 10).

defined as impaired appreciation of social expectations or reduced
socio-emotional sensitivity upon assessment (sensitivity = 0.59,
specificity = 0.87; Table 6). Though these social cognition questionnaires show reasonable diagnostic potential, we decided that since
they are not widely used in clinical settings, this criterion should
be included as a supportive feature. Further, we have opted to use
the term ‘social cognition’ to define this criterion, but acknowledge
that this is a broad umbrella term covering a complex, multi-dimensional domain. In the current study our measurement tools
allowed us to examine the ability to understand social norm violations (SNQ) and the ability to detect and respond to people’s subtle
social cues in real life situations (RSMS), but we did not examine
other facets of social cognition such as emotion processing or theory of mind. Thus, for consistency with the literature we use
the term ‘social cognition’, but note that in the MBCI-FTD criteria
this is specifically operationalized per Appendix I.
Finally, reduced insight was included due to the frequency with
which it was reported in the clinical notes, approaching that of apathy and disinhibition. However, reduced insight was included as
a supportive feature rather than a core feature, since we could not
calculate specificity.
Depression, anxiety, and sleep problems were endorsed in 25–30%
of healthy control subjects, so were not considered specific enough
for inclusion in the MBCI-FTD criteria. Hallucinations and delusions
were present in too few individuals in the Development Group to be
considered a feature, although we note that psychosis may be present
in a subset. Similarly, emotional blunting was only explicitly reported
in one individual and was therefore not included; it may be that it is a
difficult characteristic to capture with existing measures.

moderate-severe dysphoria, behavioural disinhibition, irritability/
agitation, reduced empathy/sympathy, repetitive behaviours (simple
and/or complex), joviality/gregariousness, and appetite changes/
hyperorality. Supportive features include a neuropsychological profile
of executive dysfunction or impaired naming in the context of preserved visuospatial skills and orientation, reduced insight for cognitive or behavioural changes, and impaired social cognition.
Importantly, any MBCI-FTD supportive feature has to be paired with
the presence of at least two core features. Multiple supportive features cannot replace core features for diagnosis. Thus, three core features or two core features plus one supportive feature are required for
a diagnosis of MBCI-FTD (Table 7). Overall, the proposed MBCI-FTD
criteria correctly classify 95% (21/22) of the Development Group, with
a false positive rate in Healthy Control Group 1 of 10% (8/82)
(sensitivity = 0.96, specificity = 0.90). The decision to require three features for diagnosis was based on a sensitivity-specificity trade-off:
decreasing the number of features required to two resulted in
decreased specificity (i.e. higher false positive rate in healthy controls,
420%).
We opted to include two levels of certainty in the MBCI-FTD
diagnosis framework: ‘possible’ and ‘probable’. Possible MBCI-FTD
may be diagnosed based on behavioural and cognitive features alone,
while a pathogenic mutation or biomarker is required for a diagnosis
of probable MBCI-FTD. Possible MBCI-FTD is intended to capture cases
in which biomarkers or genetic testing may be unavailable, and we
felt it was appropriate to acknowledge this lower level of certainty in
diagnosis. This framework is largely in line with the Rascovsky et al.10
bvFTD diagnostic criteria, although there is no ‘definite’ certainty level
for MBCI-FTD, because, even if a genetic mutation is present, the nature of this prodromal phase is that it is somewhat ‘questionable’.

MBCI-FTD criteria

Validation and testing phase

We propose a set of criteria for MBCI-FTD (Table 7, features defined
in Appendix I). The core features include: apathy without

When evaluated on the prodromal bvFTD Validation Group
and Healthy Control Group 2, the criteria correctly classified 74%
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Core Features
Apathy without dysphoria
Disinhibition
Irritability/lability/agitation
Reduced sympathy or empathy
Repetitive behaviours
(simple + complex)
Joviality/gregariousness
Appetite changes/hyperorality
Supportive Features
Neuropsychological profile
Reduced insight
Poor social cognition
Overall: Meet MBCI-FTD criteria

Criteria validation

Proposed criteria for prodromal bvFTD
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Table 7 Proposed criteria for MBCI-FTD
Definition of MBCI-FTD

(37/50) of the Validation Group as MBCI-FTD, with a false positive
rate of 7% (6/83) (sensitivity = 0.74, specificity = 0.93) in healthy
controls. Evaluating the specific MBCI-FTD features on the
Validation Group and Healthy Control Group 2 yielded the results
in Table 6, and the results broken down by mutation status and
type are available in Supplementary Table 4. In brief, the criteria
classified 63% (5/8) of MAPT mutation carriers, 100% (5/5) of GRN
mutation carriers, 70% (7/10) of C9orf72 expansion carriers, 8/10
(80%) of mutation carriers with an unspecified mutation, and 12/17
(71%) of presumed sporadic cases as MBCI-FTD, indicating that
they are not strongly biased in favour of one genetic mutation, and
are applicable to presumably sporadic cases. We highlight that we
were not able to assess social cognition or insight in the NACC participants (Supplementary Table 2), so the sensitivity results in the
Validation Group are likely artificially lowered, as 31/50 participants were from NACC. We also conducted an informal post hoc review of the available data for all prodromal bvFTD Validation
Group participants, to assess whether any clinical features were

‘missed’ in the relatively smaller Development Group sample.
Upon this review, no clinical features were candidates for post hoc
inclusion in the criteria, as none were present in 420% of the
Validation Group.
When tested in the Alzheimer’s Test Group (n = 301), the MBCIFTD criteria correctly classified 84–89% of participants (false positive rate of 11–16%; specificity = 0.84–0.89). Ranges are provided as
the Alzheimer’s group data were from NACC, and social cognition
and insight were not assessed in this group. The upper limit of the
false positive rate is a conservative estimate, as it assumes both
lack of insight and impaired social cognition would be present in
all participants. Finally, we divided the Alzheimer’s Test Group
into those with and without Lewy body pathology. In the
Alzheimer’s disease without Lewy body group (n = 178) the criteria
correctly classified 84–89% (false positive rate of 9–13%; specificity = 0.87–0.91), and in the Alzheimer’s disease with Lewy body
group (n = 114) the criteria correctly classified 80–86% (false positive rate of 14–20%; specificity = 0.80–0.86). Finally, it is possible
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A clinical syndrome defined by the presence of persistent and progressive decline in behaviour and/or cognition for more than six months based
on observation or history provided by knowledgeable informant.
1. Must be present to diagnose MBCI-FTD
A. Concern regarding behavioural and/or cognitive change from previous functioning, per informant, clinician, or patient
B. Preserved instrumental activities of daily living (unless due to physical impairment, e.g. motor neuron disease or parkinsonism)
C. 418 years old
2. Possible MBCI-FTD
At least three of the following core features (A–G) are sufficient, and must represent a change from previous behaviour, to diagnose possible
MBCI-FTD
A. Apathy without moderate-severe dysphoria
B. Behavioural disinhibition
C. Irritability or agitation
D. Loss of empathy or sympathy
E. Repetitive behaviours (either E1 or E2)
E1. Simple: Aberrant motor behaviour, or restlessness (e.g. pacing, fidgeting, tapping)
E2. Complex: Perseverative, compulsive or ritualistic behaviour (e.g. rigidity, rituals, hoarding)
F. Joviality or gregariousness
G. Appetite changes/hyperorality
If only two of the above core features (A–G) are present, then at least one of the following (H or I or J) must also be present to diagnose Possible
MBCI-FTD:
H. Neuropsychological deficits in context of intact or relatively preserved time/place orientation and visuospatial skills (one of H1–H2 must
be present)
H1. Clinical impairment or clinically significant decline on executive tasks (e.g. verbal generation, set-shifting, etc.)
H2. Clinical impairment or clinically significant decline on naming tests
I. Reduced insight for at least one aspect of behavioural or cognitive change
J. Impairments on standardized measures of social cognition (one of J1-J2 must be present)
J1. Reduced understanding or awareness of social expectations
J2. Low socioemotional sensitivity
3. Probable MBCI-FTD
Both of the following (A–B) must be present to diagnose Probable MBCI-FTD:
A. Meets criteria for Possible MBCI-FTD
B. Genetic or biomarker evidence of FTLD (at least one of B1–B3 must be present)
B1. Presence of a known pathogenic mutation
B2. Imaging evidence of FTD
B2.1 Frontal and/or anterior temporal atrophy on MRI or CT
B2.2 Frontal and/or anterior temporal hypoperfusion or hypometabolism on PET or SPECT
B3. Other plasma/CSF biomarkers indicative of FTLD pathology
4. Exclusionary criteria for MBCI-FTD
A. History of sudden onset or other medical conditions severe enough to account for symptoms (e.g. cerebrovascular, infectious, toxic, inflammatory, or metabolic disorders, traumatic brain injury or brain tumour)
B. Plasma or CSF or molecular imaging biomarkers more consistent with Alzheimer’s disease than FTLD
C. Meets diagnostic criteria for Probable bvFTD
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that Lewy body pathology would have only contributed to the clinical presentation in participants with neocortical (diffuse) Lewy
bodies, as all participants had Braak stage 53.60 In this subset
(n = 32), 78–87% were correctly classified by the MBCI-FTD criteria
(false positive rate of 13–22%; specificity = 0.78–0.87).

Discussion

insight. We also note that although insight is intact in some
patients, those with poor insight might be unreliable in their
reports of neuropsychiatric symptoms. Self-report, affected by insight, is the gold standard method of assessment for several important neuropsychiatric symptoms, including mood (e.g.
dysphoria), anxiety, and obsessions. The interaction between insight and self-reported neuropsychiatric symptoms in bvFTD is an
important direction for future prospective research.
In line with Rascovsky et al.10 we found a dysexecutive neuropsychological profile to be most characteristic of the prodromal
bvFTD Development Group. Naming impairments were also frequently observed, while time/place orientation and visuospatial
skills remained intact. If multiple assessments are available, a
clinically significant decline in executive functioning or naming
may be judged by a clinical neuropsychologist as sufficient for the
patient to meet this criterion. Unlike the Rascovsky et al.10 and
Neary et al.9 criteria, the relative preservation of episodic memory
is not an MBCI-FTD requirement. Inspection of the neuropsychological testing revealed amnestic impairments in a subset of participants, and there are many reports of memory problems in early
bvFTD.7,17,29 Memory complaints are common in early bvFTD,11
but may not necessarily be reflective of true amnesia (e.g. word
finding difficulties are often reported as memory problems, even if
they reflect language dysfunction). We included the neuropsychological profile as a supportive feature, given its relatively low specificity. Additional neuropsychological tests of executive function
and language (e.g. Hayling Test,64 spontaneous speech), or clinical
use of more sensitive cognitive tests (e.g. NIH-EXAMINER),65 would
perhaps allow for a better defined neuropsychological profile more
specific to bvFTD.
With regard to social cognition: quantifying social cognitive
deficits in bvFTD remains a flourishing research endeavour. It is
challenging because there is wide variability in the general population, leading to difficulty establishing normative cut-offs; recent
studies suggest that longitudinal changes on tests such as the
RSMS may be more informative than a score at a single point in
time.54 In addition, many tests are highly specific to certain cultures, rendering poor generalizability. In the current study, we
only had access to a limited set of questionnaires, and therefore,
in the MBCI-FTD criteria, we suggest that reduced social cognition
can be at least partially captured by tests gauging understanding
of social expectation violations or sensitivity to socio-emotional
cues. However, we did not have any measures gauging other
aspects of social cognition such as emotion processing, or indeed
any non-questionnaire tests of social cognition, many of which are
useful in quantifying social cognitive deficits in bvFTD. Examples
include the Social Cognition and Emotional Assessment (SEA or
mini-SEA),66,67 The Awareness of Social Inference Test,68–70 or
 animations71,72). We leave
Theory of Mind tests (e.g. Frith-Happe
open the possibility that the social cognition criterion (Criterion 2:
J) may in the future include objective impairments in other facets
of social cognition, or on other measures capturing the aspects of
social cognition examined in the current study.
Unexpectedly, hallucinations or delusions did not appear to be
a feature of prodromal bvFTD in our cohort. Psychotic features are
relatively common in FTD patients with C9orf72 or GRN mutations,14,52,73–79 and psychosis may precede other FTD symptoms by
years.76,80,81 However, in the Development Group only three participants reported delusions and/or hallucinations. Even in the
Validation Group, which was more heterogeneous than the
Development Group, none of the participants experienced hallucinations, and only two (4%) had delusional thoughts. This should
be explored further, and regional differences should be taken into
account (e.g. UK versus USA). The presence of adult-onset
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In this study, we developed and tested a proposed set of diagnostic
criteria for MBCI-FTD, representing the clinical prodrome of
bvFTD. We emphasize that all features must represent a change
from previous functioning, per informant report or multiple
evaluations.
Unsurprisingly, the criteria bear strong similarity to the
Rascovsky et al.10 bvFTD diagnostic criteria. However, we encourage clinicians to impose a somewhat lower threshold for accepting
a feature as ‘present’ for MBCI-FTD diagnosis. Rascovsky et al.10
specified that symptoms should be ‘persistent’ or ‘recurrent’, but
with patients in the very earliest symptomatic stages it is difficult
to have confidence that a feature has been ‘persistent’, or existed
over a period of time. Nevertheless, features should be represented
by more than single or rare events, so repeated behaviours, even if
mild or questionable, should be included (except in the case of irritability/agitation, which should be significant or moderate, per
Appendix I).
There are several other key differences between the Rascovsky
et al.10 criteria and the MBCI-FTD criteria worth highlighting. First,
the apathy criterion in MBCI-FTD was only considered ‘present’
when it occurred in the absence of moderate-severe dysphoria.
This was an a priori decision, as early bvFTD is often misdiagnosed
as depression.61 A handful of participants in the prodromal bvFTD
Validation Group did display moderate-severe dysphoria, so this
should not be an exclusion criterion, but we hope that requiring
the presence of apathy to be qualified by a lack of dysphoria will
aid in differentiating early bvFTD from depression. Further, recent
evidence indicates that apathy and anhedonia are correlated but
separable symptoms in FTD.62 In the current study we did not
measure anhedonia, but future research should assess the related
symptoms of dysphoria, apathy, and anhedonia in bvFTD, and
how dissociable they are during the prodromal phase. It may be
that anhedonia is a key early feature, perhaps even more relevant
than apathy.
Another feature not typically associated with early bvFTD is irritability/agitation, though this was one of the most frequently
reported features in our prodromal bvFTD group. Indeed, reviewing the clinical notes revealed multiple descriptions of patients
being ‘quick to anger’ and ‘flying off the handle’. This is an interesting finding that should be investigated; it may be that this feature peaks during the prodrome, before a more blunted emotional
presentation predominates.
Reduced insight into behavioural or cognitive changes was present in both previous iterations of the FTD criteria (Lund/
Manchester; Neary et al.9), but was removed from the Rascovsky et
al.10 criteria. We included it as a supportive feature for two main
reasons. First, although we could only obtain this information
from the clinical notes, it was almost as common as apathy and
disinhibition, indicating that it is an important feature. Second, insight or concern may be a key feature in discriminating bvFTD
from psychiatric disorders, such that insight is generally reduced
in the former and preserved in the latter.63 Features such as a lack
of insight or lack of concern, for which we have some evidence of
clinical utility and specificity, should be prospectively objectively
measured in FTD cohorts. If a reliable informant is not available,
the clinician should exercise caution in making inferences about
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Finally, we were not able to evaluate the role of biomarkers in
this study, and the biomarker criterion (Criterion 3: B3) is intended
to capture a wide range of biomarkers that may become available
in the future. As biomarker research continues to rapidly advance,
these criteria can undergo revision, and clinical feature requirements may be relaxed; for example, two clinical features may be
sufficient for an MBCI-FTD diagnosis in the context of strong biomarker evidence. This is a proposition especially worth considering for clinical trial enrolment when a genetic mutation is present
(see Supplementary Table 5 for sensitivity and specificity analyses
of the criteria when two features are required).
We have proposed the first preliminary diagnostic criteria for
prodromal bvFTD, or MBCI-FTD, leveraging data from one of the
largest prodromal bvFTD cohorts reported to date. The criteria correctly classified 95% of the prodromal bvFTD group on which they
were developed, and 74% of a separate, more heterogeneous cohort (Validation Group). False positive rates were low, in both
healthy controls (7–10%) and individuals with prodromal
Alzheimer’s disease (11–16%). These criteria represent a step towards defining a clinical prodrome of bvFTD, and will be valuable
for clinical trial enrolment, and for early diagnosis and counselling. Future research should prioritize validation in other, larger
cohorts.
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psychotic features should not necessarily guide clinicians away
from an FTD workup.
We emphasize that the ideal definitions of the neuropsychiatric/behavioural features remain unknown, and different instruments define features differently. Broad features may end up as a
‘catch all’ for many behavioural changes: for example, disinhibition may include gambling, reckless driving, approaching strangers, offensive joking, wearing malodorous clothing, and stealing.
In some cases, focal features may be included under the umbrella
of the broader feature (e.g. excessive joviality classified as disinhibition). We separated out features where we could, as a movement away from broad definitions and towards more specific, and
potentially more clinically useful, definitions of pathological behaviour. Refining definitions will aid in distinguishing FTD from
psychiatric disorders (e.g. disinhibition in bipolar disorder is different from disinhibition in FTD),82 as well as other neurodegenerative disorders, as neuropsychiatric features are common across
neurodegenerative diseases.83,84 Similarly, more refined operational definitions (e.g. apathy versus anhedonia62) may aid the development of precise measures of these features, and indeed more
accurate clinicopathological correlations.
These preliminary criteria come with caveats regarding their
sensitivity and specificity. First, the relatively small Development
Group sample size, and the limited availability of the clinical
notes, opens the possibility that some features were ‘missed’. We
attempted to mitigate this by conducting full reviews of all available data in the whole prodromal bvFTD group, but the possibility
remains. The sample size also contributed to uncertainty in the
estimated sensitivity values (i.e. wide confidence intervals). Thus,
it will be of high importance to establish the sensitivity of these
criteria in larger cohorts of prodromal bvFTD, such as the GENFI
study, and particularly in sporadic disease. Our sample of presumed sporadic bvFTD cases was small because we required
pathological confirmation of FTLD and a clinical evaluation during
the disease prodrome, and such cases are rare. Nonetheless, the
results were promising as the criteria performed well in classifying
this sample (71%). Furthermore, although we established the specificity of the criteria against prodromal Alzheimer’s disease, a longer-term goal should be to establish their utility in differentiating
between prodromal bvFTD and other rarer neurodegenerative diseases, as well as primary psychiatric disorders. Positive and negative predictive value of these criteria will need to be prospectively
determined in various clinical settings. We were bound by the
available data in this study, and that led to a dichotomous present
versus absent scoring system; it is possible that an ‘uncertain’ rating might have improved the sensitivity of the criteria.
It is also worth highlighting that there is significant overlap in
clinical features between FTLD phenotypes, and that the boundaries between diagnostic categories are often blurred; for example,
disinhibition and social cognitive dysfunction are commonly present in primary progressive aphasia and progressive supranuclear
palsy, and motor dysfunction (e.g. parkinsonism) may develop in
bvFTD.85 The MBCI-FTD criteria were developed using patients
who went on to be diagnosed with bvFTD per the Rascovsky et al.10
criteria, but there is a high chance that the MBCI-FTD criteria will
diagnose individuals who will ultimately also end up with other
FTLD disorders. Thus, although we use the term ‘bvFTD’ in discussing this prodromal state, as this is the currently accepted terminology in the field, we expect the criteria to be applicable to
individuals exhibiting the behavioural syndrome associated with
FTD, and not necessarily limited to the subset who will receive a
‘pure’, categorical diagnosis of bvFTD.
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Appendix I
Definition and operationalization of each feature included in the proposed MBCI-FTD criteria.

MBCI-FTD criterion definition
Important that each of these features represents a change from previous functioning

Apathy without moderate-severe dysphoria

Apathy is defined as a lack of interest in or indifference towards usual or previously
rewarding activities (e.g. the patient may no longer be interested in hobbies), reduced
interest in the activities of others, a loss of motivation, a lack of spontaneity,
decreased initiation of activities or social interactions (e.g. the patient may require
prompting to finish a task, does not begin or sustain conversations with family or
friends), social withdrawal, a loss of drive. This criterion should not be considered
present if the patient reports moderate-severe dysphoria (per self-report or self-completed questionnaire, such as the Geriatric Depression Scale or the Beck Depression
Inventory). We strongly caution against using caregiver or informant reports of depression here, because a lack of motivation may be interpreted by family members as
depressed mood.
Behavioural disinhibition may occur in or out of the social context, and may manifest
as: impulsive, rash or careless actions (e.g. extreme spending, gambling, reckless
driving, stealing, sharing confidential information such as a credit card number, talking to strangers as though they are friends, touching strangers), socially inappropriate behaviour (e.g. using inappropriate coarse or rude language, inappropriate
laughing, offensive jokes, sexually-explicit or hurtful comments), a loss of manners
or decorum (e.g. cutting in line, belching, picking teeth), or a disregard for personal
hygiene (e.g. wearing stained clothing). Behavioural disinhibition applies even if one
understands and regrets an action. Note that if the patient is displaying excessive
joviality, this should not be counted under disinhibition but rather as its own feature.
Irritable or agitated patients tend to be overreactive, labile, impatient, or ‘cranky’. They
may be resistant to help and hard to handle at times, and may shout at family members or others, or even hit or kick. Patients experiencing irritability or agitation may
have difficulty coping with delays or waiting for planned activities. Caregivers might
describe labile patients as being ‘quick to anger’ or ‘flying off the handle’. Mild irritability that does not represent a significant decline or change in behaviour should
not be included here. This is distinct from pseudobulbar affect, which is not part of
this criterion.
Repetitive behaviours may be simple or complex in nature. Simple perseverative behaviours might include: tapping, pacing, fidgeting, wrapping string, handling buttons or
other small objects, rubbing, clapping, humming, rocking, lip pursing, lip smacking,
picking or scratching, throat clearing. Complex perseverative behaviours include
compulsive and/or ritualistic behaviours. Examples include: collecting objects, hoarding, counting, cleaning rituals, walking fixed routes, lining up objects in a particular
order, checking.
Patients who display joviality or gregariousness may be described as being more jocular, outgoing, friendly, or jolly than usual. The patient may act excessively happy or
be overly sociable, and may appear to ‘feel too good’.
In the MBCI-FTD criteria, appetite changes may be present in either direction [hyperphagia (overeating), or hypophagia (undereating)], as per the Neuropsychiatric
Inventory. However, based on clinical experience, we highlight that hyperphagia is
the more common appetite change in prodromal bvFTD, and it is rare for a prodromal
bvFTD patient to be hypophagic, unless there is concomitant amyotrophic lateral
sclerosis (ALS). Appetite changes may manifest as an increased preference for certain
types of food, particularly sweet foods or carbohydrates, or may display rigid food
preferences. Patients may engage in binge eating, and in some cases gain significant
amounts of weight. (Note, however, that in cases of ALS weight loss may be
observed.). Patients may increase their consumption of alcohol or cigarettes.
Hyperorality, or the tendency to want to put objects in the mouth, may also be
observed.
Reduced empathy or sympathy is defined as a reduced ability to read others’ emotional
cues or understand another’s point of view. It may manifest as a diminished responsiveness to others’ feelings or needs, or a lack or personal warmth. Patients may appear indifferent to the feelings of others, or display a lack of regard for others’
distress (affective empathy). The ability to take the perspective of others is an important aspect of empathy (cognitive empathy), and therefore patients who have difficulty ‘seeing things from someone else’s point of view’ are considered to have poor
empathy. Reduced social engagement is also a common presentation of reduced

Behavioural disinhibition

Irritability/agitation

Repetitive behaviours (simple and complex)

Joviality/gregariousness

Appetite changes/hyperorality

Reduced empathy or sympathy

(continued)
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Poor social cognition

empathy, though care should be taken to ensure that this is not simply due to apathy
(a lack of motivation to engage). Caregivers may report that the patient who lacks
empathy is ‘emotionally distant’. In terms of gathering this information in a clinical
context, we strongly suggest that reduced empathy or sympathy is ascertained from
clinical interview with a caregiver or informant. Questionnaires (such as the
Interpersonal Reactivity Index Empathic Concern or Perspective Taking subscale)
may be used for informant report, but we highlight that scores should be interpreted
against appropriate normative data.
Reduced insight can be ascertained by a discrepancy between the reports of caregivers
or informants and patients themselves. The patient may exhibit poor insight for cognitive changes, behavioural changes, or both. Patients with motor symptoms (e.g.
from ALS) may deny or minimize these symptoms. A lack of insight into any behavioural or cognitive change is enough for this feature to be present. Importantly, the
clinician should make a judgement on the reliability of the informant; if the informant has very little contact with the patient, or if it appears they may be overestimating symptoms because of their own mental state (e.g. high stress or anxiety over
diagnosis), their report may be given less weight. If no informant is available, clinicians should be careful in marking this criterion as present.
The neuropsychological profile of MBCI-FTD is defined as a clinical impairment on executive function tests (e.g. set-shifting, letter fluency, cognitive inhibition, abstract
reasoning, planning, etc.) or naming tests, in the context of intact or relatively preserved time/place orientation and visuospatial skills. If there is an impairment or
relative weakness in orientation or visuospatial functioning, this criterion is not met.
We acknowledge that although in the MBCI-FTD criteria a clinical impairment on at
least one test is required (demographically-adjusted z-score 4 –1.5), clinically significant relative impairments, especially if observed across multiple tests within the
same domain, should not be discounted. Likewise, change from previous cognitive
functioning or from estimated prior functioning should be considered. However, this
judgment should only be made by trained clinical neuropsychologists. We also caution against using screening tests, such as the Mini-Mental State Examination, as the
sole tool to determine the neuropsychological profile of the patient. Finally, given the
pervasiveness of executive dysfunction, and its tendency to affect performance in
other cognitive domains (e.g. complex figure drawing, memory testing), we strongly
advise that this criterion be applied based on the judgment of a clinical neuropsychologist, and not subject or informant complaints.
The ‘poor social cognition’ criterion should only be applied if there is meaningfully
reduced performance on a validated measure of social cognition. In developing the
MBCI-FTD criteria, we examined only two aspects of social cognition: understanding
of social expectations and socioemotional sensitivity. Reduced understanding of social expectations refers to a lack of ‘social semantic knowledge’, or a lack of knowledge of the contexts in which certain behaviours are appropriate, and specifically
refers to a tendency to break social rules. For example, indicating that it is acceptable
to laugh when someone else trips and falls. The endorsement of breaking multiple
social norms is particularly specific to FTD. In the current study we have used the
Social Norms Questionnaire, but note that this instrument is highly specific to North
American culture and is not necessarily suitable for use outside North America unless it is adapted. Poor socioemotional sensitivity refers to a sensitivity and responsiveness to subtle emotional expressions during face-to-face interactions, for
example having the ability to control how one comes across to others depending on
the impression they want to give. Socioemotional sensitivity can be measured with
the Revised Self-Monitoring Scale. We highlight that it is likely that there are other
aspects of social cognition (e.g. theory of mind) that will prove to be useful for this criterion, and we strongly recommend that future studies consider using other social
cognition tools in the context of the MBCI-FTD criteria. This criterion will benefit
from future refinement, and we intend for this criterion to encompass impairments
on social cognition tasks beyond the two tests we had access to in the current study
Caution is recommended when assessing social cognition, as this ability varies widely in the general population; therefore, special care must be taken to ensure that this
represents a change from previous functioning.

The presence of behavioural/neuropsychiatric features can be ascertained by clinical interview and with questionnaires, such as the Neuropsychiatric Inventory,86 the Frontal
Behavioral Inventory,87 the Frontal Systems Behavior Scale,88 or the Cambridge Behavioural Inventory.89
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